Genito-urinary tumors, including prostate, urothelial, renal, and testis tumors, have historically presented significant therapeutic challenges due to their limited responses to traditional treatments like chemotherapy. Over the past decade, immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape for many solid tumors, particularly renal and urothelial carcinomas, by improving survival outcomes. However, the efficacy of ICI in prostate and testis cancers remains limited. Recent advancements in targeted therapies, such as new-generation tyrosine-kinase inhibitors (TKI), antibody-drug conjugates (ADC), and anti-FGFR drugs, are reshaping the treatment paradigm for these tumors. Despite these advancements, there is a pressing need to identify prognostic and predictive biomarkers to aid in patient selection and treatment personalization, which remains an underexplored area. Understanding the latest developments in immunotherapy and novel agents is crucial for their clinical application and to address the existing gaps in the field.
This Research Topic aims to evaluate the safety and efficacy of immunotherapy and novel treatment regimens in genito-urinary tumors. It seeks to explore the mechanisms of action of these therapies and investigate the pathways of resistance. Additionally, the research will focus on identifying potential biomarkers and drug targets for immunotherapy and novel treatments, such as ADCs, TKIs, and vaccines, in genito-urinary tumors. The goal is to enhance the understanding of these treatments and improve patient outcomes through tailored therapeutic strategies.
To gather further insights into the prognostic factors for immunotherapy and novel treatments in genito-urinary tumors, we welcome articles addressing, but not limited to, the following themes:
- Novel immunotherapeutic drugs or targeted therapeutic drugs for genito-urinary tumors
- Biomarkers with prognostic or predictive value in patients with genito-urinary tumors
- Clinical studies focusing on novel agents and combinations in patients with genito-urinary tumors
- Molecular mechanisms involved in the progression of genito-urinary tumors and development of drug resistance
- Novel approaches for biomarker detection using tissue, blood, or urine
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases, which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo), are out of scope for this Research Topic.
Article types and fees
This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:
Brief Research Report
Case Report
Classification
Clinical Trial
Editorial
FAIR² Data
FAIR² DATA Direct Submission
General Commentary
Hypothesis and Theory
Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.
Article types
This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
